These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 12669375)

  • 1. Recent developments in mucosal immunomodulatory adjuvants.
    Harandi AM; Sanchez J; Eriksson K; Holmgren J
    Curr Opin Investig Drugs; 2003 Feb; 4(2):156-61. PubMed ID: 12669375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Adamsson J; Anjuère F; Clemens J; Czerkinsky C; Eriksson K; Flach CF; George-Chandy A; Harandi AM; Lebens M; Lehner T; Lindblad M; Nygren E; Raghavan S; Sanchez J; Stanford M; Sun JB; Svennerholm AM; Tengvall S
    Immunol Lett; 2005 Mar; 97(2):181-8. PubMed ID: 15752556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y; Kiyono H
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential of CpG oligodeoxynucleotides as mucosal adjuvants.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Crit Rev Immunol; 2001; 21(1-3):103-20. PubMed ID: 11642598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of CpG DNA as a mucosal vaccine adjuvant.
    McCluskie MJ; Weeratna RD; Payette PJ; Davis HL
    Curr Opin Investig Drugs; 2001 Jan; 2(1):35-9. PubMed ID: 11527008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of immunostimulatory oligonucleotides.
    Uhlmann E; Vollmer J
    Curr Opin Drug Discov Devel; 2003 Mar; 6(2):204-17. PubMed ID: 12669456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of second-generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity.
    Wang D; Kandimalla ER; Yu D; Tang JX; Agrawal S
    Vaccine; 2005 Apr; 23(20):2614-22. PubMed ID: 15780444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
    Cox E; Verdonck F; Vanrompay D; Goddeeris B
    Vet Res; 2006; 37(3):511-39. PubMed ID: 16611561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J; Harandi AM; Czerkinsky C
    Expert Rev Vaccines; 2003 Apr; 2(2):205-17. PubMed ID: 12899572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG DNA as a potent inducer of mucosal immunity: implications for immunoprophylaxis and immunotherapy of mucosal infections.
    Harandi AM; Holmgren J
    Curr Opin Investig Drugs; 2004 Feb; 5(2):141-5. PubMed ID: 15043387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant.
    Horner AA; Raz E
    Clin Immunol; 2000 Apr; 95(1 Pt 2):S19-29. PubMed ID: 10729234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection.
    Parez N; Fourgeux C; Mohamed A; Dubuquoy C; Pillot M; Dehee A; Charpilienne A; Poncet D; Schwartz-Cornil I; Garbarg-Chenon A
    J Virol; 2006 Feb; 80(4):1752-61. PubMed ID: 16439532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal adjuvants.
    Freytag LC; Clements JD
    Vaccine; 2005 Mar; 23(15):1804-13. PubMed ID: 15734046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in vaccine adjuvants.
    Singh M; O'Hagan D
    Nat Biotechnol; 1999 Nov; 17(11):1075-81. PubMed ID: 10545912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Starch microparticles as vaccine adjuvant.
    Rydell N; Stertman L; Sjöholm I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):807-28. PubMed ID: 16296780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing immunogenicity by CpG DNA.
    Jiang W; Pisetsky DS
    Curr Opin Mol Ther; 2003 Apr; 5(2):180-5. PubMed ID: 12772509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADP-ribosylating enterotoxins as vaccine adjuvants.
    Lycke N; Lebrero-Fernández C
    Curr Opin Pharmacol; 2018 Aug; 41():42-51. PubMed ID: 29702466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation using bacterial enterotoxins.
    Simmons CP; Ghaem-Magami M; Petrovska L; Lopes L; Chain BM; Williams NA; Dougan G
    Scand J Immunol; 2001 Mar; 53(3):218-26. PubMed ID: 11251877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
    Ohmura-Hoshino M; Yamamoto M; Yuki Y; Takeda Y; Kiyono H
    Vaccine; 2004 Sep; 22(27-28):3751-61. PubMed ID: 15315856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.